Genfit S.A. (NASDAQ:GNFT - Get Free Report) shares traded down 3.8% during mid-day trading on Wednesday . The stock traded as low as $3.77 and last traded at $3.79. 5,525 shares were traded during mid-day trading, a decline of 65% from the average session volume of 15,876 shares. The stock had previously closed at $3.94.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and set a $13.00 price objective on shares of Genfit in a report on Friday, October 11th.
Read Our Latest Research Report on Genfit
Genfit Price Performance
The company has a fifty day moving average of $5.05 and a two-hundred day moving average of $4.65. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61.
Genfit Company Profile
(
Get Free Report)
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Further Reading
Before you consider Genfit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genfit wasn't on the list.
While Genfit currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.